Wolfe sees attractive Eli Lilly opportunity on price drop, starts at Outperform
Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...
Hosted on MSN15d
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
But he said Eli Lilly has invested $10 billion to $15 billion to expand manufacturing capacity for its injectable drugs in ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Eli Lilly grows Milwaukee-area footprint with $40.8M warehouse acquisition — and more
Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...
Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales
Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third quarter, blaming high ...
Zacks.com on MSN3d
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
NBC Los Angeles15d
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
But he said Eli Lilly has invested $10 billion to $15 billion to expand manufacturing capacity for its injectable drugs in this year alone, which should "help to reverse some of the trends ...